Summary
In the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events [ACTIVE-I; NCT00249795], treatment with irbesartan failed to lower the risk of stroke, myocardial infarction, and vascular death compared with placebo in patients with atrial fibrillation (AF). However, irbesartan may have a role in preventing heart failure, recurrent embolic events, and cardiovascular hospitalizations in patients with AF.
- Cerebrovascular Disease
- Hypertensive Disease
- Arrhythmias Clinical Trials
- © 2009 MD Conference Express
Tools
Irbesartan Fails to Prevent Most Vascular Events in Patients with AF
Permalink:
Table of contents
Cited By...
- No citing articles found.